Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Neurovance Completes Enrollment in Abuse Liability Study

By Drug Discovery Trends Editor | August 8, 2014

Neurovance Inc. announced that it has completed enrollment in a human abuse liability (HAL) study of centanafadine (formerly EB-1020). Centanafadine is a novel non-stimulant being developed for the treatment of adults with attention deficit hyperactivity disorder (ADHD). Data from its pilot phase 2a efficacy study in adult ADHD presented at a scientific meeting earlier this year demonstrated efficacy in a range similar to stimulants. This new trial is designed to evaluate the abuse liability potential for centanafadine among recreational stimulant users. Results are expected during fall 2014.
 
“This is the second major advancement in the development of centanafadine for adult ADHD,” said Anthony McKinney, president and CEO of Neurovance. “First, centanafadine’s efficacy was demonstrated in a pilot study presented at the Society of Biological Psychiatry Annual Scientific Meeting in May. Now this substantial HAL study will test centanafadine’s abuse profile against two powerful stimulants and placebo. If this registration-level study confirms the preclinical data, we can be more confident that centanafadine has the potential for less restrictive scheduling than the stimulants currently used to treat ADHD.”
 
Neurovance expects to demonstrate that centanafadine SR, a norepinephrine- and dopamine-preferring triple reuptake inhibitor, has the right ratio for the right patient, without abuse liability. The HAL study is a five-arm clinical study designed to evaluate the abuse liability potential for centanafadine at two doses among qualified recreational stimulant users compared to Schedule II comparators d-amphetamine or lisdexamfetamine (Vyvanse) or placebo. The leading products for ADHD are stimulants, which are heavily restricted due to abuse liability. In preclinical testing, centanafadine did not show stimulant activity and it is expected to have reduced risk of abuse and diversion.
 
The HAL study was designed by a team of abuse liability testing experts at Altreos Inc. of Toronto and is being conducted by Vince & Associates Clinical Research of Overland Park, Kansas, a CRO with expertise in conducting complex clinical pharmacology studies.
 
Date: August 7, 2014
Source: Neurovance

Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE